Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) Director Sells 5,369 Shares of Stock

Key Points

• Director Bethany Sensenig sold 5,369 shares of Supernus Pharmaceuticals at an average price of $42.25, totaling approximately $226,840.
• Analysts have upgraded Supernus Pharmaceuticals, with Cantor Fitzgerald raising its price target from $42.00 to $46.00 and assigning an "overweight" rating.
• Institutional investors have shown increased interest, with firms like Raiffeisen Bank and Versant Capital Management acquiring new stakes in Supernus Pharmaceuticals.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) Director Bethany Sensenig sold 5,369 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total transaction of $226,840.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN traded up $1.56 during midday trading on Friday, reaching $44.88. 1,047,668 shares of the company's stock were exchanged, compared to its average volume of 1,064,514. The company's 50 day simple moving average is $35.41 and its two-hundred day simple moving average is $33.69. The firm has a market capitalization of $2.52 billion, a PE ratio of 39.03 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $45.01.

Analyst Ratings Changes

A number of equities analysts have recently commented on SUPN shares. Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday. Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Finally, Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, Supernus Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $41.00.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Ashford Capital Management Inc. lifted its holdings in Supernus Pharmaceuticals by 1.4% during the 2nd quarter. Ashford Capital Management Inc. now owns 574,372 shares of the specialty pharmaceutical company's stock valued at $18,104,000 after purchasing an additional 7,816 shares during the last quarter. Public Sector Pension Investment Board increased its position in Supernus Pharmaceuticals by 0.3% in the 2nd quarter. Public Sector Pension Investment Board now owns 220,304 shares of the specialty pharmaceutical company's stock valued at $6,944,000 after acquiring an additional 573 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its position in Supernus Pharmaceuticals by 5.7% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 61,936 shares of the specialty pharmaceutical company's stock valued at $1,954,000 after acquiring an additional 3,336 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Supernus Pharmaceuticals by 255.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,245 shares of the specialty pharmaceutical company's stock valued at $134,000 after acquiring an additional 3,051 shares in the last quarter. Finally, Corient Private Wealth LLC acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at about $248,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.